Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A.
Debora Bertaggia CalderaraRita MarchiAna Patricia Batista Mesquita SauvageStéphane DurualFrancisco Javier GomezMaxime G ZermattenAlessandro AliottaAlessandro CasiniLorenzo AlberioPublished in: Thrombosis and haemostasis (2023)
Our study enriches the knowledge on the use of GCA to monitor non-factor replacement therapy, indicating that TG and FCF could act as direct markers of emicizumab biological activity. GCA allow to capture and visualize the individually variable response to emicizumab, leading a step forward to the personalization of patient treatment.